INTRODUCTION TO CAR T-CELL IMMUNOTHERAPY FOR CANCER
===================================================

Tumor initiation and progression is sculpted by host immunity ([@B62]; [@B16]). Since recent US FDA approval of the cancer immunotherapeutic agents, sipuleucel-T and ipilimumab, for the treatment of prostate cancer and melanoma, respectively, immunotherapy has joined surgery, radiotherapy, and chemotherapy as a conventional modality of treatment for non-hematologic malignancies. Melanoma has been a particular target of immunotherapy because of its inherent immunogenicity, and early therapeutic approaches such as interleukin-2 (IL-2) and interferon-alpha2b (IFNα~2b~) aimed to stimulate these antitumor immune responses ([@B37]; [@B54]). Recently, monoclonal antibodies (mAb) that inhibit immune checkpoint signaling molecules such as CTLA4 (via iplimumab; [@B22]; [@B71]), PD1 or PD-L1, ([@B20]; [@B68]) have shown recruitment of cytotoxic T-cell responses. *Ex vivo* expansion of tumor infiltrating lymphocytes (TIL) also aims to boost the melanoma-specific immune response and has shown impressive results for selected patients ([@B55]; [@B3]). While most of these therapies rely on a pre-existing immune response to tumor-associated antigens (TAA), the adoptive transfer of T cells genetically engineered to express novel TAA-specific receptors enables delivery of an antitumor immunotherapy even in the absence of intrinsic tumor-specific immunity ([@B52]). The T cells may express either a transgenic TCR or a chimeric antigen receptor (CAR) and of the two types of gene modification, CAR T cells have shown the most promise in clinical trials, with over 51 CAR clinical trials currently registered in the US alone (clinicaltrials.gov).

A first-generation CAR typically comprises an antigen-binding ectodomain of a mAb-derived single chain variable fragment (scFv) and a signaling endodomain from the CD3ζ molecule. Following expression, the CAR re-directs the specificity of the T cell toward the cognate antigen. Unlike TCR, CAR are independent of MHC-restricted antigen presentation, which is a feature of immune evasion by many different cancers ([@B61]; [@B60]), and instead can bind directly to TAA, albeit those located at the cell surface. They can also include multiple intracellular signaling domains from costimulatory molecules. For example, second-generation CAR may contain CD3ζ and CD28 signaling domains, while third-generation CAR may contain CD3ζ, CD28 and either OX40 (CD134) or 4-1BB (CD137). T cells expressing these later generation CAR demonstrate enhanced activation and effector function ([@B49]). Autologous CAR T cells have shown promising objective responses in leukemia and neuroblastoma patients, including some complete and partial regressions ([@B48]; [@B47]; [@B17]). However, reports of serious adverse events (AEs) in some of these early trials have raised safety concerns about the technology (see **Table [1](#T1){ref-type="table"}**).

###### 

Reports of life-threatening and fatal adverse events in CAR T-cell clinical trials.

  Trial                                             Event                                                                                                                                                                                                                                                         Reference
  ------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------
  CAIX CAR T cells (first generation)               Grade 3 and 4 transient liver enzyme increases at 1--2 × 10^9^ total cell dose as on-target toxicity related to CAIX expression on bile duct, preventable by pre-treatment with anti-CAIX monoclonal antibody.                                                [@B31], [@B30]
  CD19 CAR T cells (second generation)              Tumor lysis syndrome at 3 × 10^8^/kg total cell dose (1.46 × 10^5^/kg CAR T cells), resolved by day 26 after infusion. Severe cytokine-release syndrome, reversible by monoclonal antibody blockade at 1 × 10^8^/kg cell dose (1.2 × 10^7^/kg CAR T cells).   [@B47], [@B17]
  HER2/neu (ERBB2) CAR T cells (third generation)   Respiratory distress and death at 1 × 10^10^ total cell dose, likely due to CAR T cell localization to the lung and "cytokine storm."                                                                                                                         [@B39]
  CD19 CAR T cells (second generation)              Renal failure, "sepsis-syndrome," elevated cytokine levels and death at 1.2 × 10^7^/kg, possibly due to a combination of sepsis, cyclophosphamide treatment and T-cell transfer.                                                                              [@B7]

CAR T-CELL-RELATED SAFETY CONCERNS
==================================

The major safety concern for CAR T-cell products is the risk of on-target but off-tumor effects resulting from T-cell activation in response to normal tissue expression of the TAA. Similar off-tumor side-effects have been reported for approved mAb therapies such as trastuzumab (anti-HER2), which has cardiotoxicity in some patients due to targeting of HER2-mediated cardiomyocyte survival pathways, and cetuximab (anti-EGFR), which produces skin rashes and mucosal irritation related to EGFR expression on epithelial cells ([@B46]; [@B10]). In a more recent example, a phase 1 trial of an anti-EphA2 mAb/cytotoxic drug conjugate was discontinued due to serious AEs of clinical bleeding and coagulation probably because of endothelial-cell targeting ([@B1]). Transgenic TCR T cells likewise feature off-tumor side effects including one trial which reported MART-1- and gp100-specific T-cell killing of normal melanocytes, with the majority of patients experiencing widespread erythematous skin rash, transient uveitis or hearing loss, with most symptoms reversed upon local steroid treatment ([@B27]). While in another trial, transgenic TCR T cells specific for the colorectal TAA CEA have resulted in severe transient colitis ([@B45]). Thus there are multiple reports of toxicity by TAA-targeted cell therapies, and TAA-specific CAR T cells may also result in the targeting of healthy tissues.

There is also the theoretical risk of insertional mutagenesis and oncogenic expansion of transduced cells with retroviral-based gene therapy. Indeed, such an event has been reported in a gene-therapy trial for X-linked Severe Combined Immunodeficiency (X-SCID) in which patients received retrovirally transduced CD34^+^ bone marrow progenitor cells and four out of nine patients then developed acute T-leukemia. It is believed that insertional mutagenesis in the *LMO2* proto-oncogene together with subsequent massive proliferation of the transduced CD34^+^ progenitor population in immunodeficient hosts contributed to T-leukemogenesis ([@B19], [@B18]). In contrast, similar AEs have not been observed in trials of adoptive transfer of autologous, polyclonal gene-modified mature T cells in immunocompetent hosts ([@B21]; [@B59]). However, there is evidence in murine model systems that mono- or oligo-clonal mature T-cell populations are more susceptible to insertional mutagenesis ([@B43], [@B42], [@B41]). Most CAR T cells to date have been manufactured from polyclonal peripheral blood T cells ([@B13]), and even selected CAR T cells remain polyclonal in respect of their endogenous TCR repertoire ([@B69]). Nevertheless, insertional mutagenesis remains a concern and is another consideration in long-term clinical monitoring, which is a routine part of gene transfer trials and which helps to establish the safety profile of CAR T cells.

In addition, CAR T cells may also produce on-target, on-tumor toxicities more familiar with other cancer therapies. For example, the tumor lysis syndrome (TLS; [@B73]; [@B26]), cytokine release syndrome (CRS) and the related macrophage activation syndrome (MAS) that are associated with some chemotherapies and targeted- or immuno-therapies ([@B65]; [@B66]). Importantly these AEs may occur during the destruction of tumors, and thus even a successful, on-tumor CAR T-cell effect might result in toxicity that requires intervention.

CAR T-CELL-RELATED SERIOUS ADVERSE EVENTS
=========================================

Specific examples of these toxicities have been observed in several CAR T-cell clinical trials (see **Table [1](#T1){ref-type="table"}**). Interestingly, evident on-target, off-tumor toxicity does not require the incorporation of additional T-cell costimulatory domains into the CAR construct. In a trial of autologous T-cells expressing a first-generation CAR directed toward carbonic anhydrase IX (CAIX) in patients with metastatic renal cell carcinoma, NCI-CTC grade 3 or 4 liver function abnormalities were observed in 4 of 12 patients. This toxicity was subsequently prevented by pre-treatment with an anti-CAIX mAb ([@B31], [@B30]).

Two fatal AEs have been reported in phase 1 clinical trials of an anti-HER2 CAR ([@B39]) and of an anti-CD19 CAR ([@B44]). In the third-generation (CD28.4-1BB.ζ) anti-HER2 CAR trial, a patient with pulmonary metastases of colorectal cancer received lymphodepleting chemotherapy followed by an intravenous dose of 10^10^ HER2-CAR T cells. Within 4 h, the patient developed acute respiratory distress and died 5 days later with multi-organ failure. The investigators attributed her death to a "cytokine storm" hypothesized to result from T-cell activation on binding of CAR T cells to HER2-expressing bronchial epithelium. In the trial of a second-generation (CD28.ζ) anti-CD19 CAR, patients received lymphodepleting chemotherapy followed by 1.2--3 × 10^7^ CD19-CAR T cells/kg. One patient developed persistent fevers, respiratory distress and progressive acute renal failure, and died 44 h post-infusion. Unlike other patients enrolled in this study, this patient's serum cytokine levels were abnormally high after the chemotherapy and before the CAR T-cell infusion but no higher after the CAR T-cell infusion, and the patient's death was thus attributed to undetected sepsis. However, the direct attribution of these CAR-related AEs to on-target effects is confounded by other factors such as high T-cell dose, first-pass through the pulmonary vasculature after intravenous administration, unintended consequences of conditioning treatments, and possible underlying infection.

Although second-generation CARs incorporating the CD28 or the 4-1BB costimulatory domains have generally been safe ([@B6], [@B5]; [@B58]), other reports indicate that serious on-target toxicities including TLS and CRS have occurred ([@B7]; [@B28]; [@B47]; [@B29]; [@B17]). Four of 8 patients receiving second-generation (CD28.ζ)CD19-specific CAR T cells for progressing B-cell malignancies experienced acute and reversible toxicities, the severity of which correlated with serum cytokine levels ([@B29]). In a trial in chronic lymphoid leukemia (CLL) patients, one patient developed TLS after infusion of second-generation (4-1BB.ζ)CD19-CAR T cells requiring hospitalization on day 22 and treatment with fluid resuscitation and rasburicase, with symptoms resolving by day 26 ([@B47]). In a separate trial of CD19-CAR T cells in acute lymphoblastic leukemia (ALL) patients, two patients experienced CRS and for one patient this resulted in hospitalization on day 4 and transfer to intensive care on day 5 after the T-cell infusion ([@B17]). The CRS was reversed by anti-cytokine therapy including tocilizumab (anti-IL-6 receptor mAb) and etanercept (decoy TNF receptor). This patient went on to develop a complete remission, while the other patient had a relapse of CD19-negative leukemia after 2 months. High levels of IL-10 and IL-6 were also detected in these patients, which suggests a MAS induced by non-physiologic T-cell activation ([@B35]).

As a general statement, early clinical investigation of any CAR T cell of novel specificity may result in unpredictable on-target, off-tumor toxicity. Hence, suicide gene technology can provide a valuable "safety switch" in these at-risk clinical scenarios, allowing for the targeted deletion of inappropriately activated CAR T cells. Also, although we have focused on CAR T-cell-related toxicities in this review, it is worth noting that two patient deaths have been reported for each of two different MAGE-A3-specific transgenic TCR T cells, which resulted from either neurologic toxicity when brain-expressed MAGE-A12 was cross-targeted ([@B38]) or cardiac toxicity when heart muscle-expressed Titin was cross-targeted ([@B32]). The incidence of these toxicities, and of tumor burden-related CRS and MAS after CD19-CAR T cell therapy for B-leukemia ([@B36]), may be ameliorated by a "safety-switch" if the suicide gene system chosen is sufficiently rapid in onset.

THE iCasp9 SUICIDE GENE
=======================

The herpes simplex virus-thymidine kinase (HSV-TK) suicide gene system has long been used in cell therapy investigations as a method for depleting transduced cells in the case of AEs ([@B51]; [@B11]), However, major disadvantages attend its use for this purpose. Activation of HSV-TK by ganciclovir is relatively slow, requiring 3 days to have a complete effect *in vitro* ([@B34]) and although mutant versions of TK have improved drug sensitivity and killing ([@B70]) the viral TK gene product has intrinsic immunogenicity that may cause transduced cells to be rejected by the host immune system in immunocompetent individuals ([@B53]; [@B2]). Additionally, if ganciclovir is used to treat CMV infections in immunocompromised recipients of hemopoietic stem transplants then the use of this suicide gene would result in the unwanted deletion of transduced cells ([@B4]; [@B57]).

An alternative suicide gene system is CaspaCIDe®;, which consists of an inducible caspase 9 (iCasp9) gene together with the small-molecule, bio-inert, chemical induction of dimerization (CID) drug, AP1903. The iCasp9 gene contains the intracellular portion of the human caspase 9 protein, a pro-apoptotic molecule, fused to a drug-binding domain derived from human FK506-binding protein ([@B12]; [@B64]; see **Figure [1](#F1){ref-type="fig"}**). Intravenous administration of AP1903 produces cross-linking of the drug-binding domains of this chimeric protein, which in turn dimerizes caspase9 and activates the downstream executioner caspase 3 molecule, resulting in cellular apoptosis. The pharmacokinetics of AP1903 has been studied in a placebo-controlled, escalating-dose study in volunteers and the drug has been found to be safe and well tolerated to the highest dose of 1 mg/kg, with plasma levels directly proportional to administered dose and rapid reduction to 1% of the maximum plasma concentration by 10 h ([@B24]).

![**Activation of iCasp9 results in the death of transduced cells.** Inducible caspase 9 (iCasp9) is produced in the transduced cell as a homodimer with a drug-binding domain. Administration of CID (AP1903 or AP20187) results in dimerization of caspase 9 leading to an activated form of the molecule, which then initiates a signaling cascade leading to apoptosis of the transduced cell.](fphar-05-00235-g001){#F1}

In an early preclinical study of this system, it was shown that expression iCasp9 in, retrovirally transduced Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs) in the absence of CID had no effect on the phenotype or function of the transduced cells. However, a single 10 nM dose of CID killed 89--93% of transduced cells by day 7, as measured by GFP expression. These results were confirmed *in vivo* in a SCID mouse-human xenograft model where a single dose killed over 99% of circulating human GFP^+^ T cells by day 3. Importantly, killing *via* iCasp9 has been found to be extremely rapid with early apoptotic Annexin V^+^ cells appearing within 30 min, and a complete effect observed by 24 h of CID treatment *in vitro* ([@B34]).

Other preclinical studies have demonstrated the feasibility of including retrovirally encoded iCasp9 in cells intended for human therapy. One study investigated the use of iCasp9-transduced donor T cells to reduce the risk of donor T-cell-induced graft-versus-host disease (GvHD) in recipients of a haploidentical stem cell transplant ([@B67]). Allodepleted donor T cells were transduced with a retroviral vector encoding both iCasp9 and a truncated CD19 molecule as a selectable marker and were shown to retain effector functions after expansion and magnetic selection for the CD19^+^ population. When these donor T cells were activated with allogeneic PBMC, 10 nM CID effectively killed activated cells within 24 h *in vitro* while sparing non-activated virus-specific T cells.

Another study using a mouse model of T-cell mediated tissue destruction has also shown that the iCasp9/CID system can be used to rapidly eliminate T cells and block an ongoing autoimmune attack *in vivo* ([@B14]). In this model, iCasp9-transduced, ovalbumin (OVA)-specific OT-I transgenic T cells destroyed OVA-expressing pancreatic β-cells, and led to the rapid induction of diabetes and weight-loss that required euthanasia within 1 week of T-cell administration. However, CID administration removed 85% of transgenic OT-I T cells within 2 days, and significantly inhibited diabetes development so that mice only experienced transient diabetes or remained normo-glycemic. In this study, homeostatic expansion of OT-I T cells was also completely halted by CID administration, which provides support for the use of the iCasp9/CID system in adoptive T-cell therapies provided to lymphodepleted patients.

The first preclinical description of CAR T cells including an iCasp9 gene was reported by [@B23] who developed second-generation CD19-CAR T cells that co-expressed IL-15 and iCasp9. The authors demonstrated that these iCasp9/CAR.19/IL-15 T cells had improved effector function and were effectively eliminated *in vivo* within 3 days of CID administration, as measured by live imaging of luciferase-positive CAR T cells ([@B23]). A third-generation, anti-CD20 CAR expressing iCasp9 has likewise demonstrated 90% reduction in peripheral blood CAR T cells *in vivo* 12 h after CID administration on two consecutive days ([@B8]). A study of anti-CD19 CAR T cells co-expressing a modified hygromycin resistance/HSV-TK suicide gene fusion found that transferred T cells did not persist in patients due to anti-transgene immune responses against the resistance or suicide genes, which highlights the need for close clinical monitoring of vector persistence and anti-transgene immunity in clinical trials of T cells expressing iCasp9 ([@B25]).

The iCasp9/CID system has been successfully translated to a clinical setting. A trial of donor T-cell transfer in stem cell transplant patients demonstrated that iCasp9 could eliminate transferred T-cells and end GvHD in patients ([@B15]). Five patients who had received CD34^+^ haploidentical stem cell transplants for relapsed leukemia were given allodepleted donor T-cells transduced to express iCasp9 and the truncated CD19 selectable marker. The sorted, CD19^+^ CD3^+^ transgenic T-cells were 90--93% pure, and were able to survive and expand when transferred to patients. Skin GvHD occurred in four of the five patients and liver GVHD occurred in one patient 14--42 days after T-cell transfer. Treatment of these patients with a single dose of AP1903 (CID) reduced the numbers of circulating transgenic T cells by 90% within 30 min of administration, but had no effect on endogenous T cells and did not cause any AEs. Within 24 h, the GvHD-associated skin abnormalities were terminated and did not return, however, non-alloreactive virus-specific transgenic T cells were subsequently identified in patient blood. A long-term follow up of this clinical study has confirmed that the patients have maintained immune reconstitution, including virus-specific donor T cells, without recurrence of GvHD 3.5 years after the initial T-cell infusion ([@B75]). Other trials of iCasp9 gene transfer in haploidentical donor T cells are also ongoing (NCT01494103, ACTRN12614000290695).

An important aspect of the iCasp9/CID system is that it enables the specific killing of highly activated cells with high levels of transgene expression. As retroviral vectors preferentially integrate near transcription start sites and genes involved in proliferation ([@B72]; [@B51]; [@B9]), it is an inherent feature of the technology that actively dividing cells will have higher transgene expression and hence higher levels of iCasp9. Pre-clinical work suggests that transduced CTLs that are not killed by CID administration express insufficient iCasp9 to allow functional activation by CID ([@B64]). However, it has been observed that activation of surviving T cells with down-modulated transgene expression can rapidly restore CID sensitivity ([@B67]). In the GvHD clinical trial, this incomplete depletion of transduced cells allowed for the re-expansion of the small population of non-alloreactive CD3^+^CD19^+^ T cells remaining after AP1903 treatment. These T cells were rapidly killed when activated and re-exposed to AP1903 *ex vivo,* indicating that the surviving population remained sensitive to AP1903-mediated killing ([@B15]). Notwithstanding these results, another *in vitro* study has found that immune-selected CTLs remaining after CID treatment have little or no proliferative potential or functional transgene activity. The study also found that immune-selected CTLs rested for 8--9 days after last antigen stimulation can be depleted significantly by CID treatment ([@B50]). Hence, the functional significance of the iCasp9^+^T cells surviving CID treatment remains an open area of investigation. In the event of AP1903 administration for serious AEs related to either on-target, on-tumor or on-target, off-tumor effects, the persistence and reactivity of transgene-containing CAR T cells will need to be determined *via* studies of patient tissue samples, which may include attempted *ex vivo* re-expansion of transgene-containing T cells.

FUTURE DIRECTIONS: iCasp9-CAR CLINICAL STUDIES
==============================================

Autologous iCasp9-expressing CAR T cells are being clinically evaluated in actively recruiting trials. Our imminent phase 1 trial will investigate GD2-specific and iCasp9-expressing CAR (GD2-iCAR) T cells in advanced melanoma patients (CARPETS, ACTRN12613000198729). Autologous patient T cells will be transduced with a retroviral vector encoding a third-generation GD2-specific CD28.OX40.ζ CAR ([@B49]), which was developed by the Brenner group in a first-generation CAR format for phase 1 clinical evaluation in neuroblastoma patients ([@B48]; [@B33]), and then modified further to encode iCasp9 ([@B76]). This third-generation GD2-iCAR is also currently being investigated in an open phase 1 trial in neuroblastoma patients (GRAIN, NCT01822652), sarcoma patients (VEGAS, NCT01953900) and other GD2^+^ solid tumors (NCT02107963).

GD2 is a disialoganglioside upregulated on the cell surface of tumors of neuroectodermal origin. The GD2-specific ch14.18 mAb, which has been included in standard treatment regimens for high-risk neuroblastoma ([@B74]), has the same antigen-binding domain as the 14g2a mAb, which donated the scFv for the GD2-CAR ([@B48]; [@B33]). Ch14.18, 14g2a and other GD2-specific mAb can elicit toxicities such as fever, rash, hypotension, and painful peripheral neuropathy ([@B56]; [@B40]), which probably results from complement activation ([@B63]). Although such toxicities are possible in any clinical trial of GD2-CAR T cells, no significant AEs were observed in the clinical study of the first-generation GD2-CAR ([@B48]; [@B33]). Compared to earlier generation receptors, the improved proliferation, CTL activity and cytokine secretion of the third-generation GD2-iCAR ([@B49]) may add to the risk of toxicity either from enhanced tumor lysis, or on-target, off-tumor effects on healthy tissues, and thus inclusion of iCasp9 offers the means to mitigate these risks.

CAR T cells have shown great initial promise in the clinic but this has been accompanied by some severe and even fatal side-effects. By significantly improving its safety profile, the iCasp9/AP1903 suicide gene technology can complement CAR T-cell technology and advance its more widespread adoption in the clinic.
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